nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—ACVR1B—pancreatic cancer	0.0257	0.0467	CbGpPWpGaD
Plerixafor—CXCR4—Peptide GPCRs—SSTR3—pancreatic cancer	0.0142	0.0258	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—NDRG1—pancreatic cancer	0.0139	0.0252	CbGpPWpGaD
Plerixafor—CXCR4—Peptide GPCRs—SSTR1—pancreatic cancer	0.0136	0.0247	CbGpPWpGaD
Plerixafor—CXCR4—Peptide GPCRs—SSTR2—pancreatic cancer	0.0131	0.0238	CbGpPWpGaD
Plerixafor—CXCR4—Peptide GPCRs—CCKBR—pancreatic cancer	0.0127	0.023	CbGpPWpGaD
Plerixafor—CXCR4—Peptide GPCRs—CCKAR—pancreatic cancer	0.00945	0.0171	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—PRLHR—pancreatic cancer	0.00786	0.0143	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—SSTR3—pancreatic cancer	0.00669	0.0121	CbGpPWpGaD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—NOTCH1—pancreatic cancer	0.00661	0.012	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—SSTR1—pancreatic cancer	0.00641	0.0116	CbGpPWpGaD
Plerixafor—CXCR4—Peptide GPCRs—AGTR1—pancreatic cancer	0.00635	0.0115	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—PPY—pancreatic cancer	0.00629	0.0114	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—SSTR2—pancreatic cancer	0.00617	0.0112	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—PRLHR—pancreatic cancer	0.00616	0.0112	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—SMAD4—pancreatic cancer	0.00601	0.0109	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CCKBR—pancreatic cancer	0.00596	0.0108	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—SRC—pancreatic cancer	0.00578	0.0105	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—SSTR3—pancreatic cancer	0.00564	0.0102	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—VEGFA—pancreatic cancer	0.00563	0.0102	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—KDR—pancreatic cancer	0.0056	0.0102	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—SSTR1—pancreatic cancer	0.00541	0.00982	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—PPY—pancreatic cancer	0.0053	0.00963	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—NOTCH1—pancreatic cancer	0.00528	0.00958	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—PRLHR—pancreatic cancer	0.00527	0.00957	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—SSTR3—pancreatic cancer	0.00523	0.0095	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—SSTR2—pancreatic cancer	0.00521	0.00945	CbGpPWpGaD
Plerixafor—CXCR4—Syndecan-4-mediated signaling events—MMP9—pancreatic cancer	0.00515	0.00934	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—TERT—pancreatic cancer	0.00514	0.00933	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—SSTR1—pancreatic cancer	0.00502	0.00911	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—HIF1A—pancreatic cancer	0.00491	0.00892	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—SSTR2—pancreatic cancer	0.00483	0.00877	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—CCKBR—pancreatic cancer	0.00467	0.00847	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CCK—pancreatic cancer	0.00463	0.00841	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—SSTR3—pancreatic cancer	0.00448	0.00814	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CCKAR—pancreatic cancer	0.00444	0.00806	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—SSTR1—pancreatic cancer	0.0043	0.0078	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—PPY—pancreatic cancer	0.00422	0.00765	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—SSTR2—pancreatic cancer	0.00414	0.00751	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—PRLHR—pancreatic cancer	0.00402	0.00729	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCKBR—pancreatic cancer	0.004	0.00726	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—CNR2—pancreatic cancer	0.00381	0.00692	CbGpPWpGaD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—CXCL8—pancreatic cancer	0.00364	0.0066	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—AKT1—pancreatic cancer	0.00359	0.00652	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PIK3CG—pancreatic cancer	0.00357	0.00648	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—CNR2—pancreatic cancer	0.00354	0.00642	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—SST—pancreatic cancer	0.00351	0.00637	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—CCKAR—pancreatic cancer	0.00348	0.00631	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—SSTR3—pancreatic cancer	0.00342	0.0062	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—SSTR1—pancreatic cancer	0.00327	0.00594	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—PPY—pancreatic cancer	0.00321	0.00583	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—SSTR2—pancreatic cancer	0.00315	0.00572	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCK—pancreatic cancer	0.00311	0.00564	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—CCKBR—pancreatic cancer	0.00304	0.00552	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CNR2—pancreatic cancer	0.00303	0.0055	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—AGTR1—pancreatic cancer	0.00299	0.00542	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCKAR—pancreatic cancer	0.00298	0.00541	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—SST—pancreatic cancer	0.00296	0.00538	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—TGFB1—pancreatic cancer	0.00283	0.00514	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PIK3CB—pancreatic cancer	0.00274	0.00497	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—CNR1—pancreatic cancer	0.00273	0.00496	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—VEGFA—pancreatic cancer	0.00259	0.0047	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—CNR1—pancreatic cancer	0.00254	0.00461	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—SCT—pancreatic cancer	0.00248	0.0045	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—MMP9—pancreatic cancer	0.00238	0.00432	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—CCK—pancreatic cancer	0.00237	0.0043	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—SST—pancreatic cancer	0.00236	0.00428	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—AGTR1—pancreatic cancer	0.00234	0.00424	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—CNR2—pancreatic cancer	0.00231	0.00419	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—GLP1R—pancreatic cancer	0.00231	0.00419	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—CCKAR—pancreatic cancer	0.00227	0.00412	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—SRC—pancreatic cancer	0.00219	0.00398	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CNR1—pancreatic cancer	0.00217	0.00395	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—STAT3—pancreatic cancer	0.00211	0.00384	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—SHH—pancreatic cancer	0.00207	0.00376	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PRLHR—pancreatic cancer	0.00206	0.00374	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—IAPP—pancreatic cancer	0.00204	0.00371	CbGpPWpGaD
Plerixafor—CXCR4—islet of Langerhans—pancreatic cancer	0.00201	0.434	CbGeAlD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—AGTR1—pancreatic cancer	0.002	0.00364	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—PTHLH—pancreatic cancer	0.00196	0.00356	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—PTCH1—pancreatic cancer	0.00196	0.00356	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—SSTR3—pancreatic cancer	0.00193	0.0035	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—GDI1—pancreatic cancer	0.00189	0.00343	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—GDI2—pancreatic cancer	0.00189	0.00343	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—SSTR1—pancreatic cancer	0.00185	0.00336	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PPY—pancreatic cancer	0.00181	0.00329	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—SST—pancreatic cancer	0.00179	0.00326	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—SSTR2—pancreatic cancer	0.00178	0.00323	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—SSTR3—pancreatic cancer	0.00175	0.00318	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—CCKBR—pancreatic cancer	0.00172	0.00312	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—SSTR1—pancreatic cancer	0.00168	0.00305	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PIK3CA—pancreatic cancer	0.00167	0.00303	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—CNR1—pancreatic cancer	0.00166	0.003	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—AKT1—pancreatic cancer	0.00165	0.003	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PPY—pancreatic cancer	0.00165	0.00299	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PRSS1—pancreatic cancer	0.00163	0.00297	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ZNRF3—pancreatic cancer	0.00163	0.00297	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—SSTR2—pancreatic cancer	0.00162	0.00294	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—GCG—pancreatic cancer	0.0016	0.0029	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CCKBR—pancreatic cancer	0.00156	0.00284	CbGpPWpGaD
Plerixafor—Skin disorder—Sunitinib—pancreatic cancer	0.00156	0.0035	CcSEcCtD
Plerixafor—Erythema—Fluorouracil—pancreatic cancer	0.00155	0.00348	CcSEcCtD
Plerixafor—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.00153	0.00344	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—AGTR1—pancreatic cancer	0.00153	0.00277	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.00151	0.0034	CcSEcCtD
Plerixafor—Ill-defined disorder—Irinotecan—pancreatic cancer	0.0015	0.00337	CcSEcCtD
Plerixafor—Urticaria—Tamoxifen—pancreatic cancer	0.00149	0.00334	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—GAST—pancreatic cancer	0.00148	0.00268	CbGpPWpGaD
Plerixafor—CXCR4—Disease—DTX1—pancreatic cancer	0.00148	0.00268	CbGpPWpGaD
Plerixafor—Abdominal pain—Tamoxifen—pancreatic cancer	0.00148	0.00333	CcSEcCtD
Plerixafor—Abdominal pain—Erlotinib—pancreatic cancer	0.00146	0.00329	CcSEcCtD
Plerixafor—Ill-defined disorder—Gemcitabine—pancreatic cancer	0.00146	0.00329	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.00146	0.00328	CcSEcCtD
Plerixafor—Malaise—Irinotecan—pancreatic cancer	0.00146	0.00328	CcSEcCtD
Plerixafor—Syncope—Irinotecan—pancreatic cancer	0.00145	0.00326	CcSEcCtD
Plerixafor—Insomnia—Sunitinib—pancreatic cancer	0.00145	0.00326	CcSEcCtD
Plerixafor—Paraesthesia—Sunitinib—pancreatic cancer	0.00144	0.00324	CcSEcCtD
Plerixafor—Dyspnoea—Sunitinib—pancreatic cancer	0.00143	0.00321	CcSEcCtD
Plerixafor—Loss of consciousness—Irinotecan—pancreatic cancer	0.00142	0.0032	CcSEcCtD
Plerixafor—Malaise—Gemcitabine—pancreatic cancer	0.00142	0.00319	CcSEcCtD
Plerixafor—CXCR4—pancreas—pancreatic cancer	0.00141	0.305	CbGeAlD
Plerixafor—Dyspepsia—Sunitinib—pancreatic cancer	0.00141	0.00317	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—SCT—pancreatic cancer	0.0014	0.00255	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.00138	0.00311	CcSEcCtD
Plerixafor—Fatigue—Sunitinib—pancreatic cancer	0.00138	0.00311	CcSEcCtD
Plerixafor—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00138	0.0031	CcSEcCtD
Plerixafor—Constipation—Sunitinib—pancreatic cancer	0.00137	0.00308	CcSEcCtD
Plerixafor—Pain—Sunitinib—pancreatic cancer	0.00137	0.00308	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CXCL8—pancreatic cancer	0.00137	0.00248	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—AKT1—pancreatic cancer	0.00136	0.00247	CbGpPWpGaD
Plerixafor—Discomfort—Irinotecan—pancreatic cancer	0.00136	0.00306	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—GAST—pancreatic cancer	0.00134	0.00244	CbGpPWpGaD
Plerixafor—Asthenia—Tamoxifen—pancreatic cancer	0.00134	0.00302	CcSEcCtD
Plerixafor—Arthralgia—Gemcitabine—pancreatic cancer	0.00134	0.00302	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—CCK—pancreatic cancer	0.00134	0.00243	CbGpPWpGaD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.00133	0.003	CcSEcCtD
Plerixafor—Asthenia—Erlotinib—pancreatic cancer	0.00133	0.00299	CcSEcCtD
Plerixafor—Discomfort—Gemcitabine—pancreatic cancer	0.00132	0.00298	CcSEcCtD
Plerixafor—Pruritus—Tamoxifen—pancreatic cancer	0.00132	0.00298	CcSEcCtD
Plerixafor—Anaphylactic shock—Irinotecan—pancreatic cancer	0.00132	0.00297	CcSEcCtD
Plerixafor—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.00131	0.00295	CcSEcCtD
Plerixafor—Pruritus—Erlotinib—pancreatic cancer	0.00131	0.00294	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—CNR2—pancreatic cancer	0.0013	0.00237	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—GLP1R—pancreatic cancer	0.0013	0.00237	CbGpPWpGaD
Plerixafor—Discomfort—Fluorouracil—pancreatic cancer	0.0013	0.00293	CcSEcCtD
Plerixafor—Shock—Irinotecan—pancreatic cancer	0.0013	0.00292	CcSEcCtD
Plerixafor—Nervous system disorder—Irinotecan—pancreatic cancer	0.00129	0.00291	CcSEcCtD
Plerixafor—Haemoglobin—Docetaxel—pancreatic cancer	0.00129	0.0029	CcSEcCtD
Plerixafor—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.00128	0.00289	CcSEcCtD
Plerixafor—Haemorrhage—Docetaxel—pancreatic cancer	0.00128	0.00289	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—CCKAR—pancreatic cancer	0.00128	0.00233	CbGpPWpGaD
Plerixafor—Diarrhoea—Tamoxifen—pancreatic cancer	0.00128	0.00288	CcSEcCtD
Plerixafor—Hyperhidrosis—Irinotecan—pancreatic cancer	0.00128	0.00287	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—SCT—pancreatic cancer	0.00127	0.00231	CbGpPWpGaD
Plerixafor—Abdominal pain—Sunitinib—pancreatic cancer	0.00127	0.00285	CcSEcCtD
Plerixafor—Diarrhoea—Erlotinib—pancreatic cancer	0.00127	0.00285	CcSEcCtD
Plerixafor—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.00126	0.00284	CcSEcCtD
Plerixafor—Connective tissue disorder—Docetaxel—pancreatic cancer	0.00126	0.00284	CcSEcCtD
Plerixafor—Nervous system disorder—Gemcitabine—pancreatic cancer	0.00126	0.00284	CcSEcCtD
Plerixafor—Skin disorder—Gemcitabine—pancreatic cancer	0.00125	0.00281	CcSEcCtD
Plerixafor—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.00124	0.00279	CcSEcCtD
Plerixafor—CXCR4—Disease—DTX4—pancreatic cancer	0.00124	0.00225	CbGpPWpGaD
Plerixafor—Nervous system disorder—Fluorouracil—pancreatic cancer	0.00124	0.00279	CcSEcCtD
Plerixafor—Dizziness—Tamoxifen—pancreatic cancer	0.00124	0.00278	CcSEcCtD
Plerixafor—Dizziness—Erlotinib—pancreatic cancer	0.00122	0.00275	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PRLHR—pancreatic cancer	0.00122	0.00221	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CCK—pancreatic cancer	0.00121	0.0022	CbGpPWpGaD
Plerixafor—CXCR4—digestive system—pancreatic cancer	0.00121	0.261	CbGeAlD
Plerixafor—CXCR4—Disease—PPP2R5B—pancreatic cancer	0.00121	0.00219	CbGpPWpGaD
Plerixafor—Insomnia—Irinotecan—pancreatic cancer	0.00119	0.00268	CcSEcCtD
Plerixafor—Vomiting—Tamoxifen—pancreatic cancer	0.00119	0.00267	CcSEcCtD
Plerixafor—Paraesthesia—Irinotecan—pancreatic cancer	0.00118	0.00267	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CNR2—pancreatic cancer	0.00118	0.00215	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—GLP1R—pancreatic cancer	0.00118	0.00215	CbGpPWpGaD
Plerixafor—Hypersensitivity—Sunitinib—pancreatic cancer	0.00118	0.00265	CcSEcCtD
Plerixafor—Rash—Tamoxifen—pancreatic cancer	0.00118	0.00265	CcSEcCtD
Plerixafor—Dermatitis—Tamoxifen—pancreatic cancer	0.00118	0.00265	CcSEcCtD
Plerixafor—Vomiting—Erlotinib—pancreatic cancer	0.00118	0.00265	CcSEcCtD
Plerixafor—Dyspnoea—Irinotecan—pancreatic cancer	0.00118	0.00265	CcSEcCtD
Plerixafor—Headache—Tamoxifen—pancreatic cancer	0.00117	0.00264	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.00117	0.00263	CcSEcCtD
Plerixafor—Rash—Erlotinib—pancreatic cancer	0.00117	0.00262	CcSEcCtD
Plerixafor—Dermatitis—Erlotinib—pancreatic cancer	0.00117	0.00262	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CCKAR—pancreatic cancer	0.00116	0.00211	CbGpPWpGaD
Plerixafor—Insomnia—Gemcitabine—pancreatic cancer	0.00116	0.00261	CcSEcCtD
Plerixafor—Dyspepsia—Irinotecan—pancreatic cancer	0.00116	0.00261	CcSEcCtD
Plerixafor—CXCR4—Disease—HEY2—pancreatic cancer	0.00116	0.00211	CbGpPWpGaD
Plerixafor—Immune system disorder—Docetaxel—pancreatic cancer	0.00116	0.00261	CcSEcCtD
Plerixafor—Headache—Erlotinib—pancreatic cancer	0.00116	0.00261	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—IAPP—pancreatic cancer	0.00115	0.0021	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—CXCL8—pancreatic cancer	0.00115	0.0021	CbGpPWpGaD
Plerixafor—Paraesthesia—Gemcitabine—pancreatic cancer	0.00115	0.0026	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.00115	0.00259	CcSEcCtD
Plerixafor—Asthenia—Sunitinib—pancreatic cancer	0.00115	0.00259	CcSEcCtD
Plerixafor—Dyspnoea—Gemcitabine—pancreatic cancer	0.00115	0.00258	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—ACVR1B—pancreatic cancer	0.00114	0.00208	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ZNRF3—pancreatic cancer	0.00114	0.00208	CbGpPWpGaD
Plerixafor—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.00114	0.00257	CcSEcCtD
Plerixafor—Insomnia—Fluorouracil—pancreatic cancer	0.00114	0.00257	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.00114	0.00256	CcSEcCtD
Plerixafor—Fatigue—Irinotecan—pancreatic cancer	0.00114	0.00256	CcSEcCtD
Plerixafor—Paraesthesia—Fluorouracil—pancreatic cancer	0.00113	0.00255	CcSEcCtD
Plerixafor—Pruritus—Sunitinib—pancreatic cancer	0.00113	0.00255	CcSEcCtD
Plerixafor—Constipation—Irinotecan—pancreatic cancer	0.00113	0.00254	CcSEcCtD
Plerixafor—Pain—Irinotecan—pancreatic cancer	0.00113	0.00254	CcSEcCtD
Plerixafor—Dyspnoea—Fluorouracil—pancreatic cancer	0.00113	0.00253	CcSEcCtD
Plerixafor—Mental disorder—Docetaxel—pancreatic cancer	0.00112	0.00253	CcSEcCtD
Plerixafor—Erythema—Docetaxel—pancreatic cancer	0.00112	0.00251	CcSEcCtD
Plerixafor—Dyspepsia—Fluorouracil—pancreatic cancer	0.00111	0.0025	CcSEcCtD
Plerixafor—Nausea—Tamoxifen—pancreatic cancer	0.00111	0.0025	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00111	0.0025	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PTHLH—pancreatic cancer	0.00111	0.00201	CbGpPWpGaD
Plerixafor—Fatigue—Gemcitabine—pancreatic cancer	0.00111	0.00249	CcSEcCtD
Plerixafor—Constipation—Gemcitabine—pancreatic cancer	0.0011	0.00247	CcSEcCtD
Plerixafor—Pain—Gemcitabine—pancreatic cancer	0.0011	0.00247	CcSEcCtD
Plerixafor—Nausea—Erlotinib—pancreatic cancer	0.0011	0.00247	CcSEcCtD
Plerixafor—Diarrhoea—Sunitinib—pancreatic cancer	0.0011	0.00247	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00109	0.00245	CcSEcCtD
Plerixafor—Abdominal distension—Epirubicin—pancreatic cancer	0.00109	0.00245	CcSEcCtD
Plerixafor—Feeling abnormal—Irinotecan—pancreatic cancer	0.00109	0.00245	CcSEcCtD
Plerixafor—Pain—Fluorouracil—pancreatic cancer	0.00108	0.00243	CcSEcCtD
Plerixafor—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00108	0.00243	CcSEcCtD
Plerixafor—CXCR4—Disease—HEY1—pancreatic cancer	0.00107	0.00195	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—SHH—pancreatic cancer	0.00106	0.00193	CbGpPWpGaD
Plerixafor—Dizziness—Sunitinib—pancreatic cancer	0.00106	0.00238	CcSEcCtD
Plerixafor—Feeling abnormal—Gemcitabine—pancreatic cancer	0.00106	0.00238	CcSEcCtD
Plerixafor—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.00106	0.00238	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—IAPP—pancreatic cancer	0.00105	0.0019	CbGpPWpGaD
Plerixafor—Abdominal pain—Irinotecan—pancreatic cancer	0.00104	0.00235	CcSEcCtD
Plerixafor—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00104	0.00234	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—DTX1—pancreatic cancer	0.00104	0.00188	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SSTR3—pancreatic cancer	0.00104	0.00188	CbGpPWpGaD
Plerixafor—Vomiting—Sunitinib—pancreatic cancer	0.00102	0.00229	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—SST—pancreatic cancer	0.00101	0.00184	CbGpPWpGaD
Plerixafor—Rash—Sunitinib—pancreatic cancer	0.00101	0.00227	CcSEcCtD
Plerixafor—Dermatitis—Sunitinib—pancreatic cancer	0.00101	0.00227	CcSEcCtD
Plerixafor—Abdominal distension—Doxorubicin—pancreatic cancer	0.00101	0.00227	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—PTHLH—pancreatic cancer	0.00101	0.00183	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PTCH1—pancreatic cancer	0.00101	0.00183	CbGpPWpGaD
Plerixafor—Urticaria—Fluorouracil—pancreatic cancer	0.001	0.00226	CcSEcCtD
Plerixafor—Headache—Sunitinib—pancreatic cancer	0.001	0.00226	CcSEcCtD
Plerixafor—Syncope—Docetaxel—pancreatic cancer	0.001	0.00225	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SSTR1—pancreatic cancer	0.000993	0.0018	CbGpPWpGaD
Plerixafor—Loss of consciousness—Docetaxel—pancreatic cancer	0.000982	0.00221	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PPY—pancreatic cancer	0.000973	0.00177	CbGpPWpGaD
Plerixafor—Hypersensitivity—Irinotecan—pancreatic cancer	0.000972	0.00219	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SSTR2—pancreatic cancer	0.000955	0.00173	CbGpPWpGaD
Plerixafor—CXCR4—Disease—JAG2—pancreatic cancer	0.000953	0.00173	CbGpPWpGaD
Plerixafor—Arthralgia—Docetaxel—pancreatic cancer	0.000951	0.00214	CcSEcCtD
Plerixafor—Nausea—Sunitinib—pancreatic cancer	0.000951	0.00214	CcSEcCtD
Plerixafor—Asthenia—Irinotecan—pancreatic cancer	0.000946	0.00213	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000945	0.00213	CcSEcCtD
Plerixafor—CXCR4—Disease—MEN1—pancreatic cancer	0.000939	0.0017	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—CNR1—pancreatic cancer	0.000936	0.0017	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SLC2A2—pancreatic cancer	0.000932	0.00169	CbGpPWpGaD
Plerixafor—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000931	0.00209	CcSEcCtD
Plerixafor—Dry mouth—Docetaxel—pancreatic cancer	0.00093	0.00209	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CCKBR—pancreatic cancer	0.000923	0.00167	CbGpPWpGaD
Plerixafor—Asthenia—Gemcitabine—pancreatic cancer	0.000922	0.00207	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—SST—pancreatic cancer	0.000921	0.00167	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000918	0.00167	CbGpPWpGaD
Plerixafor—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000912	0.00205	CcSEcCtD
Plerixafor—Pruritus—Gemcitabine—pancreatic cancer	0.000909	0.00205	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—GCG—pancreatic cancer	0.000904	0.00164	CbGpPWpGaD
Plerixafor—Diarrhoea—Irinotecan—pancreatic cancer	0.000902	0.00203	CcSEcCtD
Plerixafor—Shock—Docetaxel—pancreatic cancer	0.000897	0.00202	CcSEcCtD
Plerixafor—CXCR4—Disease—SHH—pancreatic cancer	0.000896	0.00163	CbGpPWpGaD
Plerixafor—Nervous system disorder—Docetaxel—pancreatic cancer	0.000894	0.00201	CcSEcCtD
Plerixafor—Pruritus—Fluorouracil—pancreatic cancer	0.000894	0.00201	CcSEcCtD
Plerixafor—Skin disorder—Docetaxel—pancreatic cancer	0.000886	0.00199	CcSEcCtD
Plerixafor—CXCR4—Disease—IAPP—pancreatic cancer	0.000885	0.00161	CbGpPWpGaD
Plerixafor—Diarrhoea—Gemcitabine—pancreatic cancer	0.000879	0.00198	CcSEcCtD
Plerixafor—Dizziness—Irinotecan—pancreatic cancer	0.000872	0.00196	CcSEcCtD
Plerixafor—Haemoglobin—Epirubicin—pancreatic cancer	0.00087	0.00196	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—DTX4—pancreatic cancer	0.000868	0.00157	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—GLI1—pancreatic cancer	0.000868	0.00157	CbGpPWpGaD
Plerixafor—Haemorrhage—Epirubicin—pancreatic cancer	0.000866	0.00195	CcSEcCtD
Plerixafor—Diarrhoea—Fluorouracil—pancreatic cancer	0.000864	0.00194	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000862	0.00156	CbGpPWpGaD
Plerixafor—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000851	0.00191	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CNR1—pancreatic cancer	0.00085	0.00154	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HSPA1B—pancreatic cancer	0.000849	0.00154	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000844	0.00153	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NRP1—pancreatic cancer	0.000844	0.00153	CbGpPWpGaD
Plerixafor—Vomiting—Irinotecan—pancreatic cancer	0.000839	0.00189	CcSEcCtD
Plerixafor—Dizziness—Fluorouracil—pancreatic cancer	0.000835	0.00188	CcSEcCtD
Plerixafor—Rash—Irinotecan—pancreatic cancer	0.000832	0.00187	CcSEcCtD
Plerixafor—Dermatitis—Irinotecan—pancreatic cancer	0.000831	0.00187	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000831	0.00187	CcSEcCtD
Plerixafor—Headache—Irinotecan—pancreatic cancer	0.000826	0.00186	CcSEcCtD
Plerixafor—Insomnia—Docetaxel—pancreatic cancer	0.000825	0.00186	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—GCG—pancreatic cancer	0.000821	0.00149	CbGpPWpGaD
Plerixafor—Paraesthesia—Docetaxel—pancreatic cancer	0.000819	0.00184	CcSEcCtD
Plerixafor—Vomiting—Gemcitabine—pancreatic cancer	0.000817	0.00184	CcSEcCtD
Plerixafor—Dyspnoea—Docetaxel—pancreatic cancer	0.000813	0.00183	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—HEY2—pancreatic cancer	0.000812	0.00147	CbGpPWpGaD
Plerixafor—Rash—Gemcitabine—pancreatic cancer	0.00081	0.00182	CcSEcCtD
Plerixafor—Dermatitis—Gemcitabine—pancreatic cancer	0.000809	0.00182	CcSEcCtD
Plerixafor—Haemoglobin—Doxorubicin—pancreatic cancer	0.000805	0.00181	CcSEcCtD
Plerixafor—Headache—Gemcitabine—pancreatic cancer	0.000805	0.00181	CcSEcCtD
Plerixafor—Vomiting—Fluorouracil—pancreatic cancer	0.000803	0.00181	CcSEcCtD
Plerixafor—Dyspepsia—Docetaxel—pancreatic cancer	0.000803	0.00181	CcSEcCtD
Plerixafor—Haemorrhage—Doxorubicin—pancreatic cancer	0.000801	0.0018	CcSEcCtD
Plerixafor—Rash—Fluorouracil—pancreatic cancer	0.000797	0.00179	CcSEcCtD
Plerixafor—Dermatitis—Fluorouracil—pancreatic cancer	0.000796	0.00179	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—GAST—pancreatic cancer	0.000794	0.00144	CbGpPWpGaD
Plerixafor—Headache—Fluorouracil—pancreatic cancer	0.000791	0.00178	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000787	0.00177	CcSEcCtD
Plerixafor—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000787	0.00177	CcSEcCtD
Plerixafor—Fatigue—Docetaxel—pancreatic cancer	0.000786	0.00177	CcSEcCtD
Plerixafor—Nausea—Irinotecan—pancreatic cancer	0.000783	0.00176	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—AGTR1—pancreatic cancer	0.000783	0.00142	CbGpPWpGaD
Plerixafor—Immune system disorder—Epirubicin—pancreatic cancer	0.000782	0.00176	CcSEcCtD
Plerixafor—Pain—Docetaxel—pancreatic cancer	0.00078	0.00175	CcSEcCtD
Plerixafor—Constipation—Docetaxel—pancreatic cancer	0.00078	0.00175	CcSEcCtD
Plerixafor—Nausea—Gemcitabine—pancreatic cancer	0.000763	0.00172	CcSEcCtD
Plerixafor—CXCR4—Disease—JAG1—pancreatic cancer	0.00076	0.00138	CbGpPWpGaD
Plerixafor—Mental disorder—Epirubicin—pancreatic cancer	0.000758	0.00171	CcSEcCtD
Plerixafor—Erythema—Epirubicin—pancreatic cancer	0.000754	0.0017	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SCT—pancreatic cancer	0.000752	0.00137	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HEY1—pancreatic cancer	0.000752	0.00137	CbGpPWpGaD
Plerixafor—Feeling abnormal—Docetaxel—pancreatic cancer	0.000751	0.00169	CcSEcCtD
Plerixafor—Nausea—Fluorouracil—pancreatic cancer	0.00075	0.00169	CcSEcCtD
Plerixafor—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000746	0.00168	CcSEcCtD
Plerixafor—Flatulence—Epirubicin—pancreatic cancer	0.000743	0.00167	CcSEcCtD
Plerixafor—Immune system disorder—Doxorubicin—pancreatic cancer	0.000723	0.00163	CcSEcCtD
Plerixafor—CXCR4—Disease—CD44—pancreatic cancer	0.000722	0.00131	CbGpPWpGaD
Plerixafor—Abdominal pain—Docetaxel—pancreatic cancer	0.000721	0.00162	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CCK—pancreatic cancer	0.000718	0.0013	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HSPA1A—pancreatic cancer	0.000717	0.0013	CbGpPWpGaD
Plerixafor—Mental disorder—Doxorubicin—pancreatic cancer	0.000702	0.00158	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CNR2—pancreatic cancer	0.000699	0.00127	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—GLP1R—pancreatic cancer	0.000699	0.00127	CbGpPWpGaD
Plerixafor—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000699	0.00157	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—CXCL8—pancreatic cancer	0.000699	0.00127	CbGpPWpGaD
Plerixafor—Erythema—Doxorubicin—pancreatic cancer	0.000697	0.00157	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CCKAR—pancreatic cancer	0.000688	0.00125	CbGpPWpGaD
Plerixafor—Flatulence—Doxorubicin—pancreatic cancer	0.000687	0.00155	CcSEcCtD
Plerixafor—Malaise—Epirubicin—pancreatic cancer	0.00068	0.00153	CcSEcCtD
Plerixafor—Syncope—Epirubicin—pancreatic cancer	0.000676	0.00152	CcSEcCtD
Plerixafor—Hypersensitivity—Docetaxel—pancreatic cancer	0.000672	0.00151	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—JAG2—pancreatic cancer	0.000667	0.00121	CbGpPWpGaD
Plerixafor—Loss of consciousness—Epirubicin—pancreatic cancer	0.000662	0.00149	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—MEN1—pancreatic cancer	0.000658	0.00119	CbGpPWpGaD
Plerixafor—Asthenia—Docetaxel—pancreatic cancer	0.000654	0.00147	CcSEcCtD
Plerixafor—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000647	0.00146	CcSEcCtD
Plerixafor—Pruritus—Docetaxel—pancreatic cancer	0.000645	0.00145	CcSEcCtD
Plerixafor—Arthralgia—Epirubicin—pancreatic cancer	0.000642	0.00144	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000637	0.00143	CcSEcCtD
Plerixafor—Discomfort—Epirubicin—pancreatic cancer	0.000634	0.00143	CcSEcCtD
Plerixafor—Malaise—Doxorubicin—pancreatic cancer	0.000629	0.00141	CcSEcCtD
Plerixafor—Dry mouth—Epirubicin—pancreatic cancer	0.000627	0.00141	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SHH—pancreatic cancer	0.000627	0.00114	CbGpPWpGaD
Plerixafor—Syncope—Doxorubicin—pancreatic cancer	0.000625	0.00141	CcSEcCtD
Plerixafor—Diarrhoea—Docetaxel—pancreatic cancer	0.000624	0.0014	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—NOTCH4—pancreatic cancer	0.000623	0.00113	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IAPP—pancreatic cancer	0.000619	0.00112	CbGpPWpGaD
Plerixafor—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000615	0.00138	CcSEcCtD
Plerixafor—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000613	0.00138	CcSEcCtD
Plerixafor—Shock—Epirubicin—pancreatic cancer	0.000605	0.00136	CcSEcCtD
Plerixafor—Nervous system disorder—Epirubicin—pancreatic cancer	0.000603	0.00136	CcSEcCtD
Plerixafor—Dizziness—Docetaxel—pancreatic cancer	0.000603	0.00136	CcSEcCtD
Plerixafor—Skin disorder—Epirubicin—pancreatic cancer	0.000597	0.00134	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PTCH1—pancreatic cancer	0.000595	0.00108	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PTHLH—pancreatic cancer	0.000595	0.00108	CbGpPWpGaD
Plerixafor—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000595	0.00134	CcSEcCtD
Plerixafor—Arthralgia—Doxorubicin—pancreatic cancer	0.000594	0.00134	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.00059	0.00133	CcSEcCtD
Plerixafor—Discomfort—Doxorubicin—pancreatic cancer	0.000586	0.00132	CcSEcCtD
Plerixafor—Dry mouth—Doxorubicin—pancreatic cancer	0.000581	0.00131	CcSEcCtD
Plerixafor—Vomiting—Docetaxel—pancreatic cancer	0.00058	0.0013	CcSEcCtD
Plerixafor—Rash—Docetaxel—pancreatic cancer	0.000575	0.00129	CcSEcCtD
Plerixafor—Dermatitis—Docetaxel—pancreatic cancer	0.000574	0.00129	CcSEcCtD
Plerixafor—Headache—Docetaxel—pancreatic cancer	0.000571	0.00129	CcSEcCtD
Plerixafor—CXCR4—Disease—SMAD4—pancreatic cancer	0.00057	0.00103	CbGpPWpGaD
Plerixafor—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000569	0.00128	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.00056	0.00126	CcSEcCtD
Plerixafor—Shock—Doxorubicin—pancreatic cancer	0.00056	0.00126	CcSEcCtD
Plerixafor—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000558	0.00126	CcSEcCtD
Plerixafor—CXCR4—Disease—HES1—pancreatic cancer	0.000557	0.00101	CbGpPWpGaD
Plerixafor—Insomnia—Epirubicin—pancreatic cancer	0.000556	0.00125	CcSEcCtD
Plerixafor—Skin disorder—Doxorubicin—pancreatic cancer	0.000553	0.00124	CcSEcCtD
Plerixafor—Paraesthesia—Epirubicin—pancreatic cancer	0.000552	0.00124	CcSEcCtD
Plerixafor—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.00055	0.00124	CcSEcCtD
Plerixafor—Dyspnoea—Epirubicin—pancreatic cancer	0.000548	0.00123	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SST—pancreatic cancer	0.000544	0.000987	CbGpPWpGaD
Plerixafor—Nausea—Docetaxel—pancreatic cancer	0.000542	0.00122	CcSEcCtD
Plerixafor—Dyspepsia—Epirubicin—pancreatic cancer	0.000541	0.00122	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000536	0.000974	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—JAG1—pancreatic cancer	0.000532	0.000966	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000531	0.00119	CcSEcCtD
Plerixafor—Fatigue—Epirubicin—pancreatic cancer	0.00053	0.00119	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—NOTCH3—pancreatic cancer	0.00053	0.000962	CbGpPWpGaD
Plerixafor—Constipation—Epirubicin—pancreatic cancer	0.000526	0.00118	CcSEcCtD
Plerixafor—Pain—Epirubicin—pancreatic cancer	0.000526	0.00118	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000518	0.00117	CcSEcCtD
Plerixafor—Insomnia—Doxorubicin—pancreatic cancer	0.000515	0.00116	CcSEcCtD
Plerixafor—Paraesthesia—Doxorubicin—pancreatic cancer	0.000511	0.00115	CcSEcCtD
Plerixafor—Dyspnoea—Doxorubicin—pancreatic cancer	0.000507	0.00114	CcSEcCtD
Plerixafor—Feeling abnormal—Epirubicin—pancreatic cancer	0.000507	0.00114	CcSEcCtD
Plerixafor—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000503	0.00113	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CNR1—pancreatic cancer	0.000502	0.000911	CbGpPWpGaD
Plerixafor—Dyspepsia—Doxorubicin—pancreatic cancer	0.000501	0.00113	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000491	0.00111	CcSEcCtD
Plerixafor—Fatigue—Doxorubicin—pancreatic cancer	0.000491	0.0011	CcSEcCtD
Plerixafor—Urticaria—Epirubicin—pancreatic cancer	0.000489	0.0011	CcSEcCtD
Plerixafor—CXCR4—Disease—TERT—pancreatic cancer	0.000488	0.000885	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000487	0.000884	CbGpPWpGaD
Plerixafor—Constipation—Doxorubicin—pancreatic cancer	0.000487	0.00109	CcSEcCtD
Plerixafor—Pain—Doxorubicin—pancreatic cancer	0.000487	0.00109	CcSEcCtD
Plerixafor—Abdominal pain—Epirubicin—pancreatic cancer	0.000486	0.00109	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—GCG—pancreatic cancer	0.000485	0.00088	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000472	0.000856	CbGpPWpGaD
Plerixafor—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000469	0.00106	CcSEcCtD
Plerixafor—CXCR4—Disease—HIF1A—pancreatic cancer	0.000466	0.000847	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000465	0.00105	CcSEcCtD
Plerixafor—CXCR4—Disease—TSC2—pancreatic cancer	0.000465	0.000844	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AGTR1—pancreatic cancer	0.000462	0.000839	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—STK11—pancreatic cancer	0.000456	0.000827	CbGpPWpGaD
Plerixafor—CXCR4—Disease—APOE—pancreatic cancer	0.000455	0.000826	CbGpPWpGaD
Plerixafor—Hypersensitivity—Epirubicin—pancreatic cancer	0.000453	0.00102	CcSEcCtD
Plerixafor—Urticaria—Doxorubicin—pancreatic cancer	0.000452	0.00102	CcSEcCtD
Plerixafor—Abdominal pain—Doxorubicin—pancreatic cancer	0.00045	0.00101	CcSEcCtD
Plerixafor—Asthenia—Epirubicin—pancreatic cancer	0.000441	0.000993	CcSEcCtD
Plerixafor—Pruritus—Epirubicin—pancreatic cancer	0.000435	0.000979	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CD—pancreatic cancer	0.000428	0.000777	CbGpPWpGaD
Plerixafor—Diarrhoea—Epirubicin—pancreatic cancer	0.000421	0.000947	CcSEcCtD
Plerixafor—CXCR4—Disease—NOTCH1—pancreatic cancer	0.00042	0.000763	CbGpPWpGaD
Plerixafor—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000419	0.000943	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000411	0.000746	CbGpPWpGaD
Plerixafor—Asthenia—Doxorubicin—pancreatic cancer	0.000408	0.000919	CcSEcCtD
Plerixafor—Dizziness—Epirubicin—pancreatic cancer	0.000407	0.000915	CcSEcCtD
Plerixafor—CXCR4—Disease—EGF—pancreatic cancer	0.000406	0.000737	CbGpPWpGaD
Plerixafor—Pruritus—Doxorubicin—pancreatic cancer	0.000403	0.000906	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SMAD4—pancreatic cancer	0.000399	0.000725	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—CXCL8—pancreatic cancer	0.000395	0.000717	CbGpPWpGaD
Plerixafor—Vomiting—Epirubicin—pancreatic cancer	0.000391	0.00088	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—HES1—pancreatic cancer	0.00039	0.000707	CbGpPWpGaD
Plerixafor—Diarrhoea—Doxorubicin—pancreatic cancer	0.000389	0.000876	CcSEcCtD
Plerixafor—Rash—Epirubicin—pancreatic cancer	0.000388	0.000873	CcSEcCtD
Plerixafor—Dermatitis—Epirubicin—pancreatic cancer	0.000387	0.000872	CcSEcCtD
Plerixafor—Headache—Epirubicin—pancreatic cancer	0.000385	0.000867	CcSEcCtD
Plerixafor—Dizziness—Doxorubicin—pancreatic cancer	0.000376	0.000847	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CB—pancreatic cancer	0.000373	0.000677	CbGpPWpGaD
Plerixafor—Nausea—Epirubicin—pancreatic cancer	0.000365	0.000822	CcSEcCtD
Plerixafor—Vomiting—Doxorubicin—pancreatic cancer	0.000362	0.000814	CcSEcCtD
Plerixafor—CXCR4—Disease—PIK3CD—pancreatic cancer	0.000361	0.000656	CbGpPWpGaD
Plerixafor—Rash—Doxorubicin—pancreatic cancer	0.000359	0.000807	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CXCL8—pancreatic cancer	0.000359	0.000651	CbGpPWpGaD
Plerixafor—Dermatitis—Doxorubicin—pancreatic cancer	0.000358	0.000807	CcSEcCtD
Plerixafor—Headache—Doxorubicin—pancreatic cancer	0.000356	0.000802	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—TERT—pancreatic cancer	0.000342	0.00062	CbGpPWpGaD
Plerixafor—Nausea—Doxorubicin—pancreatic cancer	0.000338	0.000761	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—HIF1A—pancreatic cancer	0.000327	0.000593	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TSC2—pancreatic cancer	0.000326	0.000591	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—APOE—pancreatic cancer	0.000319	0.000579	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CB—pancreatic cancer	0.000315	0.000571	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KDR—pancreatic cancer	0.000312	0.000567	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTGS2—pancreatic cancer	0.000312	0.000566	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NFKBIA—pancreatic cancer	0.000297	0.000539	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NOTCH1—pancreatic cancer	0.000294	0.000534	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CG—pancreatic cancer	0.000288	0.000522	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—NRAS—pancreatic cancer	0.000288	0.000522	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EGF—pancreatic cancer	0.000284	0.000516	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CTNNB1—pancreatic cancer	0.000279	0.000507	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTEN—pancreatic cancer	0.000272	0.000494	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—EGFR—pancreatic cancer	0.000262	0.000476	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CD—pancreatic cancer	0.000253	0.000459	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SRC—pancreatic cancer	0.000252	0.000458	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CA—pancreatic cancer	0.000251	0.000455	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—KRAS—pancreatic cancer	0.000248	0.00045	CbGpPWpGaD
Plerixafor—CXCR4—Disease—STAT3—pancreatic cancer	0.000243	0.000442	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NRAS—pancreatic cancer	0.000243	0.000441	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CA—pancreatic cancer	0.000228	0.000413	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MYC—pancreatic cancer	0.000226	0.00041	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TGFB1—pancreatic cancer	0.000226	0.000409	CbGpPWpGaD
Plerixafor—CXCR4—Disease—EGFR—pancreatic cancer	0.000221	0.000401	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CB—pancreatic cancer	0.00022	0.0004	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CXCL8—pancreatic cancer	0.000212	0.000385	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—HRAS—pancreatic cancer	0.000211	0.000382	CbGpPWpGaD
Plerixafor—CXCR4—Disease—KRAS—pancreatic cancer	0.000209	0.000379	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—AKT1—pancreatic cancer	0.000205	0.000372	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CASP3—pancreatic cancer	0.000203	0.000368	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCND1—pancreatic cancer	0.000197	0.000358	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CTNNB1—pancreatic cancer	0.000195	0.000355	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CA—pancreatic cancer	0.000192	0.000348	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MMP9—pancreatic cancer	0.000192	0.000348	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PTEN—pancreatic cancer	0.000191	0.000346	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—AKT1—pancreatic cancer	0.000186	0.000337	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HRAS—pancreatic cancer	0.000178	0.000322	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SRC—pancreatic cancer	0.000177	0.000321	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—VEGFA—pancreatic cancer	0.000172	0.000312	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—STAT3—pancreatic cancer	0.00017	0.000309	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NRAS—pancreatic cancer	0.00017	0.000309	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MYC—pancreatic cancer	0.000158	0.000287	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TGFB1—pancreatic cancer	0.000158	0.000287	CbGpPWpGaD
Plerixafor—CXCR4—Disease—AKT1—pancreatic cancer	0.000157	0.000285	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EGFR—pancreatic cancer	0.000155	0.000281	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KRAS—pancreatic cancer	0.000146	0.000266	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CA—pancreatic cancer	0.000134	0.000244	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TP53—pancreatic cancer	0.00013	0.000236	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HRAS—pancreatic cancer	0.000124	0.000226	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AKT1—pancreatic cancer	0.00011	0.000199	CbGpPWpGaD
